Companies attempting to implement CRISPR - based technology mainstream are trying to establish delivery methods that ensure its effectiveness in the body . For the therapy to deliver it needs to be delivered to a specific tissue and then cells within the tissue . researchers are focusing on two approaches . Viral vectors involve producing a protein containing β - Cas9 to induce gene modifications . However , they need further research before they can be produced on a commercial scale . Alternatively , lipid nanoparticles are synthetic particles ideal for getting therapies into the bloodstream via the liver but they can not yet reach other tissues to deliver the treatment effectively .
Companies attempting to make CRISPR-Cas9 technology mainstream are trying to establish delivery methods that ensure its effectiveness in the body. For the therapy to work it needs to be delivered to a specific tissue and then cells within the tissue. Companies are focusing on two methods. Viral vectors involve producing a virus containing CRISPR-Cas9 to deliver gene modifications. However, they need further research before they can be produced on a commercial scale. Alternatively, lipid nanoparticles are synthetic particles ideal for getting therapies into the bloodstream via the liver but they cannot yet reach other tissues to deliver the treatment effectively.